News

The therapy is currently being evaluated for AL amyloidosis in the phase 1b/2 NEXICART-2 clinical trial (NCT06097832) in the United States.

Review top news and interview highlights from the week ending February 7, 2025.

Mark Hamilton, MD, PhD, a hematology-oncology and BMT cell therapy fellow at Stanford University, discussed implications of his institution’s findings on treatment-related secondary malignancies.

A positive mean eGFR slope was seen in 23 patients who reached 1 year of follow-up in the phase 1/2 STAAR trial.

With regard to safety, Ultragenyx characterized the gene therapy as “generally well-tolerated."

Notably, the product previously received fast track designation from the FDA for relapsed/refractory class III or class IV lupus nephritis.

The product, also known as Vigil, is being evaluated in the ongoing randomized, placebo-controlled phase 2b VITAL clinical trial.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

The hematology-oncology and BMT cell therapy fellow at Stanford University discussed implications of his institution’s findings on treatment-related secondary malignancies.

For World Cancer Day, held annually on February 4, take a look at the stories that have stood out in oncology cell therapy in recent months.

The IND clearance constitutes the first for a xenokidney product.

Catch up on any of the key data updates you may have missed last month, with coverage highlights from the CGTLive™ team.

Barry J Byrne, MD, PhD, the chief medical advisor of MDA, also shared his thoughts on the 75th anniversary of the organization.

Catch up on any of the key FDA news stories you may have missed last month, with coverage highlights from the CGTLive® team.

Review top news and interview highlights from the week ending January 31, 2025.

In Episode 1 of ImmunoLogic, Stephen J. Schuster, MD, discussed the potential of treating lymphoma without chemotherapy.

Barry J Byrne, MD, PhD, the chief medical advisor of MDA, discussed what attendees can expect at the 2025 MDA Meeting.

The company received a recommendation from the study’s IDMC to move onto enrollment for the trial’s second cohort.

The chief medical advisor of the Muscular Dystrophy Association also shared his thoughts on the 75th anniversary of the organization.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

With regard to safety, the company stated that no new safety signals have been reported.

The chief medical advisor of the Muscular Dystrophy Association discussed what attendees can expect at the 2025 MDA Meeting.

The planned phase 1 RESOLUTION study will include patients with systemic lupus erythematosus, lupus nephritis, idiopathic inflammatory myopathies, and systemic sclerosis.

Sarah Larson, MD, the medical director of the Immune Effector Cell Therapy Program at UCLA, discussed initial data from a phase 1/2 trial.

The company has begun the process of randomly assigning enrolled participants in the sham-controlled phase 2 REGENERATE-PD trial.

We've compiled a list of 5 clinical trials with expected data readouts in 2025 that are worth keeping an eye on.

David Porter, MD, the director of cell therapy and transplant at Penn Medicine, also summed up his main message regarding the current state of the field in general.

Review top news and interview highlights from the week ending January 24, 2025.